Trial · NCT04316546
MK-7075 (Miransertib) in Proteus Syndrome
NCT04316546, Phase 2, Active not recruiting, National Human Genome Research Institute (NHGRI)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MK-7075 (Miransertib) in Proteus Syndrome. Trials, record NCT04316546. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04316546
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MK-7075 (Miransertib) in Proteus Syndrome
- NCT number
- NCT04316546
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 38 participants, actual
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- Conditions
- Proteus Syndrome
- Interventions
- MK-7075 (miransertib)
- First posted
- 2020-03-20
- Last updated
- 2026-07-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CCTN | Baseline, two years | Change in CCTN involvement of the plantar surface from baseline will be used to classify each subject as either a responder or non-responder (binary) in the treated population. The primary endpoint is response rate (defined as =\< 5% increase in plantar involvement from baseline over 26 cycles). This will be assessed by blinded central photography review. |
| Secondary | Quality of life | Periodically throughout the study (described in schedule of activities) | Change from baseline in pain score (NRS-11), physical functioning (PROMIS), and quality of life (PedsQL). |
| Secondary | Long-term safety and tolerability | Periodically throughout the study (described in schedule of activities) | Periodic safety (e.g., physical examination, vital sign measurements, clinical laboratory tests, use of concomitant medications and collection of AE information) assessments. |
| Secondary | Duration of response | Periodically throughout the study (described in schedule of activities) | Duration of response is defined as the amount of time from first response signal to progression of CCTN involvement \>5% over a 26 cycle period assessed every 6-7 cycles |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04316546
GET https://conductscience.org/api/trials/v1/NCT04316546/registered